Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1799 • ACR Convergence 2021
Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis
Victoria Furer¹, Jonathan Wollman², David levartovsky³, Valerie Aloush³, Sara Borok Lev-Ran⁴, Daphna Paran⁵, Ori Elkayam³ and Ari Polachek⁶, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Herzliya, Israel, ³Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Tel AViv, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Sourasky Medical Center, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) can affect differently women and men. Ultrasound (US) is an important tool in the evaluation of disease activity of PsA. To…
Abstract Number: 1817 • ACR Convergence 2021
Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
Josef Smolen¹, Ennio Lubrano², Mitsumasa Kishimoto³, Andra R Bălănescu⁴, Vibeke Strand⁵, Tianming Gao⁶, Nancy Vranich⁶, Ralph Lippe⁷ and William Tillett⁸, ¹Medical University of Vienna, Vienna, Austria, ²Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ³Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁴“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ⁵Stanford University School of Medicine, Portola Valley, CA, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁸Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Achieving low disease activity (LDA) or remission is a main treatment target in PsA. Composite indices used to assess disease activity include Disease Activity…
Abstract Number: 1910 • ACR Convergence 2021
Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
Laure Gossec¹, Nemanja Damjanov², Shigeyoshi Tsuji³, Apinya Lertratanakul⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, Patrick Zueger⁶ and Kurt de Vlam⁷, ¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia, ³Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷Department of Rheumatology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Background/Purpose: The achievement of disease control has been shown to be associated with improved prognosis in PsA, though no single measure of low disease activity…
Abstract Number: 0059 • ACR Convergence 2021
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Lihi Eder¹, Stephane Caucheteux¹, Somi Afiuni², Adriana Krizova¹, James Limacher¹, Hartland Jackson¹ and Vincent Piguet¹, ¹University of Toronto, Toronto, ON, Canada, ²Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
Background/Purpose: Cross talk between different cell types, such as T cell subsets and other immune cell populations, is important in psoriatic disease. Imaging Mass Cytometry…
Abstract Number: 0240 • ACR Convergence 2021
Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Joseph Merola¹, Feifei Yang², Natalie Dennis³, Steven Peterson⁴, Iris Lin², Yiting Wang⁵, Soumya Chakravarty⁶, Arthur Quenéchdu³, May Shawi⁷, Claire Fischer³ and Elaine Husni⁸, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). The objectives of this study…
Abstract Number: 0751 • ACR Convergence 2021
Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
Philip Mease¹, Vibeke Strand², Dan Furst³, Evan Siegel⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford University School of Medicine, Portola Valley, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴Arthritis and Rheumatism Associates, Potomac, MD, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
Abstract Number: 1170 • ACR Convergence 2021
Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Jakub Grobelski¹, Florian Recker², Pantelis Karakostas¹, Dagmar Wilsmann-Theis³, Wolfgang Hartung⁴, Peter Brossart⁵ and Valentin Schäfer¹, ¹Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ²Centre for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany, ⁵Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
Background/Purpose: In the early detection of arthritis, such as psoriatic arthritis, ultrasound (US) of painful joints plays an important role in diagnosis. Pathological findings can…
Abstract Number: 1332 • ACR Convergence 2021
Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)
Ana-Maria Orbai¹, Laura Coates², Atul Deodhar³, Christopher Ritchlin⁴, Alexa Kollmeier⁵, Marlies Neuhold⁶, Yi-Hsuan Liu⁷, Yan Liu⁷ and Chenglong Han⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen-Cilag, Zug, Switzerland, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: It is important to assess symptoms of pain, fatigue, anxiety, depression, sleep disturbance, and impaired physical function in patients (pts) with psoriatic arthritis (PsA),…
Abstract Number: 1349 • ACR Convergence 2021
Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study
Adrian Ciurea¹, Tim Killeen², Raphael Micheroli¹, Norina N Gassman², Hyejin Jo³, Kenneth Kwok⁴, Elizabeth Kudlacz⁴, Oliver Distler¹, Caroline Ospelt⁵ and Mojca Frank-Bertoncelj¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ²Pfizer AG, Zurich, Switzerland, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Peripheral joint involvement in PsA varies. In RA, varied joint involvement may reflect site-specific differences in stromal cell transcriptome, including Janus kinase-signal transducer and…
Abstract Number: 1456 • ACR Convergence 2021
Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
Jonathan Vela¹, Salome Kristensen², Lene Dreyer², Kristian Kjær Petersen³ and Lars Arendt Nielsen³, ¹Dept. of Rheumatology Aalborg Denmark, Aalborg, Denmark, ²Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Aalborg University, Aalborg, Denmark
Background/Purpose: Medical cannabis is increasing in popularity yet the recent International Association for the Study of Pain presidential task force on cannabis and cannabinoid analgesia…
Abstract Number: 1783 • ACR Convergence 2021
National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017
Vagishwari Murugesan¹, Eleni Pilitsi², Gabriela Rabasa³ and Maureen Dubreuil⁴, ¹Boston University Medical Center, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Boston University School of Medicine/ VA Boston, Boston, MA
Background/Purpose: Given that uptake of biologic therapies has increased over recent years, we sought to investigate the national trends in serious infections in patients with…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 1818 • ACR Convergence 2021
Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Taylor Blachley², Jacqueline O’Brien², Nicole Middaugh², Greg Kricorian³, Scott Stryker³, David Collier⁴ and Alexis Ogdie-Beatty⁵, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: The burden of PsA and its chronic symptoms may have considerable impact on patient function and quality of life. Real-world research is limited on…
Abstract Number: 1920 • ACR Convergence 2021
Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
Ho Man Lam¹, Ho So², Isaac Cheng¹, Edmund Li¹, Priscilla Wong³, Tena Li¹, Alex Lee¹ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Prince of Wales Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
Abstract Number: 0060 • ACR Convergence 2021
Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
Abha Singh¹, Jessica Murillo Saich², Roxana Coras³, Julio Ramirez⁴, Eric Chang², Raquel Celis⁵, Aaron Armando², Oswald Quehenberger², Arthur Kavanaugh², Juan D Cañete⁶ and Monica Guma⁷, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ⁴Arthritis Unit, Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain, ⁷University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Oxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation. Oxylipins derived from n-6 PUFA precursors, such as arachidonic acid (AA),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].